Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Enzene’s New Jersey facility offers efficient, fully continuous or hybrid vat production within a modular framework.

I have always been a bit of a skeptic about how important AI will be for the biotechnology industry, but, given a few […] ...

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.